Updates in Cancer Therapy

Great advances in cancer treatments have been made over the last years, especially in the emerging field of cancer immunotherapy. Have a look at the selection of scientific publications, providing an insight about how important clinical research truly is, or visit our Facebook page for more information:

28. August 2020

FDA Approves Daratumumab Plus Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.

Read more

27. August 2020

Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice.

Read more

25. August 2020

FDA Pipeline: Priority Reviews for Immunotherapy Dose Regimen, Small Cell Lung Cancer; Fast Track Designations in Brain Cancer and Leukemia.

Read more

19. August 2020

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

Read more

15. August 2020

Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.

Read more

14. August 2020

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

Read more

22. July 2020

Pembrolizumab for Early
Triple-Negative Breast Cancer.

Read more

14. July 2020

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.

Read more

07. July 2020

Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors.

Read more

02. July 2020

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.

Read more

30. June 2020

FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-Positive Breast Cancer.

Read more

24. June 2020

FDA Approves Pembrolizumab for Adults and Children With Tumor Mutational Burden–High Solid Tumors.

Read more

22. June 2020

FDA Pipeline: Fast Track Designations in Colorectal and Pancreatic Cancers, Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia.

Read more

18. June 2020

TOFACITINIB FOR REFRACTORY IMMUNE-RELATED COLITIS.

Read more

16. June 2020

Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma.

Read more

15. June 2020

Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.

Read more

09. June 2020

TROPHIMMUN Trial Finds Avelumab Effective in Rare Gynecologic Tumor Resistant to Chemotherapy.

Read more

08. June 2020

PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS.

Read more

02. June 2020

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

Read more

29. May 2020

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Read more

28. May 2020

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Read more

25. May 2020

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Read more

22. May 2020

FDA Pipeline: Two Breakthrough Therapy Designations for Fam-Trastuzumab Deruxtecan-nxki, and More.

Read more

20. May 2020

VAXIMM Announces First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy VXM01 in Combination with PD-L1 Inhibitor Avelumab to be Presented at ASCO20 Virtual.

Read more

18. May 2020

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Read more

15. May 2020

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Read more

14. May 2020

FDA APPROVES SELPERCATINIB FOR LUNG AND THYROID CANCERS WITH RET GENE MUTATIONS OR FUSIONS.

Read more

13. May 2020

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

Read more

11. May 2020

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

Read more

08. May 2020

FDA GRANTS ACCELERATED APPROVAL TO SACITUZUMAB GOVITECAN-HZIY FOR METASTATIC TNBC.

Read more

07. May 2020

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

Read more

30. April 2020

Nivolumab/Ipilimumab vs Nivolumab Alone in Recurrent or Persistent Ovarian Cancer.

Read more

29. April 2020

903O - Redefining the IGCCCG classification in advanced non-seminoma.

Read more

28. April 2020

ELEVATE-TN: Acalabrutinib With or Without Obinutuzumab vs Chlorambucil/Obinutuzumab in Patients With Previously Untreated CLL.

Read more

27. April 2020

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Read more

24. April 2020

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.

Read more

23. April 2020

Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison.

Read more

22. April 2020

Selinexor Plus Dexamethasone Studied in Triple-Class Refractory Multiple Myeloma.

Read more

21. April 2020

Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma.

Read more

20. April 2020

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Read more

17. April 2020

Aspirin Use and Risk of Cancers of the Digestive Tract.

Read more

16. April 2020

Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.

Read more

15. April 2020

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.

Read more

15. April 2020

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Read more

15. April 2020

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Read more

14. April 2020

FDA Pipeline: Priority Reviews for Immunotherapy Based on Biomarker Status, Combination First-Line Therapy in Lung Cancer.

Read more

08. April 2020

KTE-X19 for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2 Trial.

Read more

07. April 2020

FDA APPROVES NERATINIB IN COMBINATION WITH CAPECITABINE FOR METASTATIC HER2-POSITIVE BREAST CANCER.

Read more

03. April 2020

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration.

Read more

03. April 2020

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.

Read more

03. April 2020

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.

Read more

02. April 2020

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Read more

02. April 2020

Combination of Ruxolitinib and PEG-INF α2 Effectively Treats Patients With Polycythemia Vera, Myelofibrosis.

Read more

31. March 2020

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.

Read more

30. March 2020

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Read more

27. March 2020

FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma.

Read more

26. March 2020

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Read more

25. March 2020

Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer

Read more

24. March 2020

Cabozantinib for Advanced Ewing Sarcoma or Osteosarcoma.

Read more

20. March 2020

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

Read more

18. March 2020

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.

Read more

17. March 2020

SUNSHINE Trial: High-Dose Vitamin D May Benefit Patients With Metastatic Colorectal Cancer

Read more

16. March 2020

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Read more

13. March 2020

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Read more

11. March 2020

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Read more

10. March 2020

Analysis of 4-Year Survival With Nivolumab in Patients Previously Treated for Advanced NSCLC

Read more

06. March 2020

ESMO 2019: PROfound: Phase 3 Study of Olaparib vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations

Read more

06. March 2020

TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations

Read more

05. March 2020

Pharmacologic management of cognitive impairment induced by cancer therapy

Read more

04. March 2020

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.

Read more

03. March 2020

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

Read more

28. February 2020

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

Read more

26. February 2020

Tumor Mutation Burden—From Doubts to Concerns—In Reply

Read more

19. February 2020

Actively personalized vaccination trial for newly diagnosed glioblastoma

Read more

19. February 2020

A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

Read more

18. February 2020

The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL

Read more

17. February 2020

Old drugs bring new hope to a cancer that lacks precision therapy

Read more

17. February 2020

Hepatocytes direct the formation of a pro-metastatic niche in the liverHepatocytes direct the formation of a pro-metastatic niche in the liver

Read more

13. February 2020

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma

Read more

12. February 2020

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.

Read more

11. February 2020

A systems mechanism for KRAS mutant allele–specific responses to targeted therapy

Read more

31. January 2020

Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study

Read more

31. January 2020

ESMO Immuno-Oncology 2018: Does Proton Pump Inhibitor Therapy Impact the Efficacy of Nivolumab Plus Ipilimumab?

Read more

29. January 2020

FDA Accepts Sacituzumab Govitecan Application for TNBC

Read more

28. January 2020

FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer

Read more

16. December 2019

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Read more

11. December 2019

Hair dye and chemical straightener use and breast cancer risk in a large US population of black and white women

Read more

25. November 2019

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Read more

20. November 2019

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features

Read more

17. November 2019

Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer

Read more

27. October 2019

First Patients Dosed in Phase 1/2 Trial Testing Galinpepimut-S, Keytruda Combo in Advanced Cancers

Read more

17. October 2019

ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Serous Ovarian Cancer

Read more

27. September 2019

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Read more

21. September 2019

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Read more

20. August 2019

Regular Aspirin Use and Risk of Hepatocellular Carcinoma and Epithelial Ovarian Cancer

Read more

06. August 2019

Do TP53 and ESR2 Interactions Change Prognosis in Triple-Negative Breast Cancer?

Read more

04. August 2019

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events

Read more

28. July 2019

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Read more

17. June 2019

FDA Approves Pembrolizumab for the First-Line Treatment of Head and Neck Squamous Cell Carcinoma

Read more

24. May 2019

SABCS 2018: KATHERINE Trial: Adjuvant Ado-Trastuzumab Emtansine vs Trastuzumab in Early-Stage HER2-Positive Breast Cancer

Read more

13. May 2019

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Read more

08. May 2019

Personalized Cancer Treatment

Read more

02. May 2019

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Read more

17. April 2019

Cancer: 'Off-the-shelf' stem cell treatment enters clinical trial

Read more

12. April 2019

Vaccine Plus Trastuzumab in Preventing Recurrence of HER2–Low-Expressing Breast Cancer

Read more

29. March 2019

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Read more

29. March 2019

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Read more

20. March 2019

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

Read more

14. March 2019

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Read more

08. March 2019

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Read more

28. February 2019

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Read more

22. February 2019

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Read more

12. February 2019

Lorlatinib Shows Overall and Intracranial Activity in ALK-Positive NSCLC

Read more

31. January 2019

PACIFIC Trial of Durvalumab Sets Standard in Stage III Unresectable NSCLC

Read more

27. January 2019

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Read more

22. January 2019

Exercise as part of cancer treatment

Read more

12. December 2018

SABCS 2018: SOLAR-1: Liquid Biopsies in Predicting Benefit of Alpelisib in PIK3CA-Mutant Breast Cancer

Read more

30. November 2018

ELOQUENT-3: Addition of Elotuzumab to Pomalidomide and Dexamethasone in Previously Treated Multiple Myeloma

Read more

24. November 2018

Obesity-induced Immune Dysfunction and its Consequences in Cancer

Read more

15. November 2018

The Mediterranean Diet Reduces the Risk and Mortality of the Prostate Cancer: A Narrative Review

Read more

11. November 2018

Exercise Therapy for Symptom Management and Treatment in Patients With Cancer

Read more

08. November 2018

Durvalumab Improves Overall Survival in Unresectable Stage III NSCLC

Read more

27. October 2018

Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses’ Health Studies

Read more

15. October 2018

Nivolumab and Ipilimumab Effective against Melanoma. That Has Spread to the Brain.

Read more

09. October 2018

The Association Between Dietary Quality and Overall and Cancer-Specific Mortality Among Cancer Survivors, NHANES III

Read more

09. October 2018

A Menu for Cancer Risk Reduction? Five truths about the role of food and diet in cancer prevention

Read more

14. August 2018

Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer

Read more

19. July 2018

What is 'checkpoint therapy' and why did it win the medicine Nobel prize?

Read more

19. July 2018

What is 'checkpoint therapy' and why did it win the medicine Nobel prize?

Read more

15. July 2018

IMpassion130: Atezolizumab Plus Nab-Paclitaxel in Metastatic or Locally Advanced Triple-Negative Breast Cancer

Read more

11. June 2018

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.

Read more

11. June 2018

Immune-System Therapy Eradicated Breast Cancer in New Breakthrough

Read more

11. May 2018

Immunotherapy and radiation in glioblastoma.

Read more

01. April 2018

Prognostic significance of marital status in breast cancer survival: A population-based study.

Read more

23. March 2018

Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival.

Read more

28. February 2018

Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.

Read more

05. February 2018

Physician age and outcomes in elderly patients in hospital in the US: observational study

Read more

30. January 2018

Proof-of-Principle Study of Combination Checkpoint Inhibitor Plus Trastuzumab in HER2-Positive Advanced Breast Cancer

Read more

26. January 2018

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Read more

20. January 2018

Preventive Effects of Cocoa and Cocoa Antioxidants in Colon Cancer

Read more

20. January 2018

American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)

Read more

18. January 2018

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer

Read more

15. January 2018

FDA Grants DS-8201 Breakthrough Designation for HER2+ Breast Cancer

Read more

28. October 2017

Clinical decision-making for immunotherapy in metastatic renal cell carcinoma

Read more

22. October 2017

Osimertinib Granted Breakthrough Therapy Designation for First-Line Treatment of EGFR Mutation–Positive NSCLC

Read more

19. October 2017

Cancers Associated With Overweight and Obesity Make Up 40% of Cancers Diagnosed in the United States

Read more

25. September 2017

FDA Approves Daratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Read more

19. September 2017

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme

Read more

06. September 2017

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Read more

05. September 2017

FDA Approves Panitumumab for Use in Wild-Type RAS Metastatic Colorectal Cancer

Read more

20. July 2017

Angiosarcoma treated successfully with anti-PD-1 therapy - a case report

Read more

12. June 2017

Genentech: Beyond The Cycle

Read more

10. June 2017

Cancer Drug Proves to Be Effective Against Multiple Tumors

Read more

08. June 2017

Immunotherapy Combination Shows Promise in Early Stage Triple Negative Breast Cancer

Read more

06. June 2017

ASCO 2017: Chance of Colon Cancer Recurrence Nearly Cut in Half in Patients Who Consume Nuts

Read more

03. June 2017

Checkpoint Inhibitors Advancing in Multiple GI Cancers

Read more

31. May 2017

Duke researchers develop treatment that triples survival time of brain cancer patients

Read more

31. May 2017

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

Read more

13. May 2017

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient

Read more

13. May 2017

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient

Read more

17. April 2017

Brain Trust: Cutting-Edge Treatments for Glioblastoma on the Rise

Read more

16. April 2017

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Read more

02. April 2017

Nivolumab in renal cell carcinoma: latest evidence and clinical potential

Read more

12. March 2017

Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

Read more

08. March 2017

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

Read more

07. March 2017

Ovarian cancer and the immune system — The role of targeted therapies

Read more

21. February 2017

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142

Read more

08. February 2017

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma: an international, multicentre, open-label, phase 2 trial.

Read more

05. February 2017

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Read more

16. November 2016

Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report

Read more

13. November 2016

Immunotherapy moves to the front lines in fight against lung cancer

Read more

09. November 2016

Impressive Early Data for Rovalpituzumab Tesirine in Small Cell Lung Cancer

Read more

24. October 2016

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Read more

12. October 2016

The Science Behind Guided Imagery

Read more

16. September 2016

Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

Read more

27. August 2016

The development and use of the E75 (HER2 369-377) peptide vaccine

Read more

27. August 2016

Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial

Read more

18. August 2016

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient

Read more

01. August 2016

Harnessing the immune system to fight cancer

Read more

13. July 2016

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

Read more

26. April 2016

Neoadjuvant T-DM1/Pertuzumab Combo Boosts pCR in HER2+ Breast Cancer

Read more

14. April 2016

Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors

Read more

14. April 2016

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial

Read more

10. March 2016

Peptide vaccines in breast cancer: The immunological basis for clinical response

Read more

25. February 2016

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial

Read more

23. January 2016

With Immunotherapy, Glimmers of Progress against Glioblastoma

Read more

15. January 2016

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

Read more

22. November 2015

Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers

Read more

22. November 2015

Adjuvant HER2/neu peptide cancer vaccines in breast cancer

Read more

09. October 2015

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study

Read more

08. October 2015

Immune modulation for cancer therapy

Read more

02. October 2015

Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy

Read more

02. October 2015

Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.

Read more

30. September 2015

Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?

Read more

News

17. March 2020

We would like to share with you a comment in regard to the corona virus pandemia.

29. January 2020

January 2020 - Up2Date in HER2-positive breast cancer: New therapy strategy available

Logo Hallwang Clinic Germany

Contact us

Contact us for a free consultation with our specialized oncology team.

Rechts